Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Planning and Dissemination Grant - Institute Community Support

McGill University

$10,000.00

5th Cancer Cachexia Conference: Bridging Molecular Advances to Clinical Care

EF 2019-20

Résumé
Cachexia is a debilitating syndrome of cancer, characterized by severe weight loss resulting from the depletion of mainly skeletal muscle and adipose. Muscle atrophy in particular is associated with weakness and fatigue, a lower tolerance to chemotherapy, and increased risk for adverse outcomes following surgery. Estimates indicate that the prevalence of cachexia in cancer is 50-80%, and 20% of all cancer deaths are linked to cachexia rather than directly to the tumor burden. Although Phase III clinical studies have been performed in cancer cachexia, they have failed to reach their primary endpoint. Thus, there remains an urgent need to better understand the underlying mechanisms by which tumor factors drive muscle and fat loss, so as to identify viable therapeutic targets that can be translated to an effective treatment. In 2012, a committee was formed to organize the first, cancer cachexia focused international conference, which was held in Boston. Based on the success of that first meeting, subsequent biennial conferences took place in Montreal (2014), Washington DC (2016), and Philadelphia (2018). The results from those meetings contributed a growing number of new laboratories entering the field and provided new knowledge. Still, much remains to be answered in the areas of clinical trial design, prognostic and diagnostic biomarkers, and choice of animal models. We propose to tackle these gaps through the organization of this meeting. As Canadian scientists, we are fortunate to have been involved in the inception of the Cancer Cachexia conference. This conference offers the unique opportunity for Canadian students and trainees to learn about the recent advances in the field, and to present their work in front leaders in the field. In addition, the conference offers venues for trainees and scientists to establish novel collaboration to solve health-related questions that are directly relevant to Canada and the world.
Programme
Planning and Dissemination Grant - Institute Community Support
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
412047
Name
Gallouzi Imed
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Planning and Dissemination - ICR
Projecttitle
5th Cancer Cachexia Conference: Bridging Molecular Advances to Clinical Care
Programtype2
Miscellaneous Programs
Orgnameinp2
McGill University
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Cachexia; Cancer; Clinicians; Decreased Quality Of Life; Inflammation; International Conference; Muscle Atrophy; Physicians; Scientists
Abstract
Cachexia is a debilitating syndrome of cancer, characterized by severe weight loss resulting from the depletion of mainly skeletal muscle and adipose. Muscle atrophy in particular is associated with weakness and fatigue, a lower tolerance to chemotherapy, and increased risk for adverse outcomes following surgery. Estimates indicate that the prevalence of cachexia in cancer is 50-80%, and 20% of all cancer deaths are linked to cachexia rather than directly to the tumor burden. Although Phase III clinical studies have been performed in cancer cachexia, they have failed to reach their primary endpoint. Thus, there remains an urgent need to better understand the underlying mechanisms by which tumor factors drive muscle and fat loss, so as to identify viable therapeutic targets that can be translated to an effective treatment. In 2012, a committee was formed to organize the first, cancer cachexia focused international conference, which was held in Boston. Based on the success of that first meeting, subsequent biennial conferences took place in Montreal (2014), Washington DC (2016), and Philadelphia (2018). The results from those meetings contributed a growing number of new laboratories entering the field and provided new knowledge. Still, much remains to be answered in the areas of clinical trial design, prognostic and diagnostic biomarkers, and choice of animal models. We propose to tackle these gaps through the organization of this meeting. As Canadian scientists, we are fortunate to have been involved in the inception of the Cancer Cachexia conference. This conference offers the unique opportunity for Canadian students and trainees to learn about the recent advances in the field, and to present their work in front leaders in the field. In addition, the conference offers venues for trainees and scientists to establish novel collaboration to solve health-related questions that are directly relevant to Canada and the world.
Competitiondate
201909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gallouzi, Imed
Approvedterm
1 an 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $10,000~ $0~